ID   NALM-6 TOP1(+/-)
AC   CVCL_HE09
SY   TOP1 (+/-) NALM-6; TOP1 +/- Nalm-6
DR   cancercelllines; CVCL_HE09
DR   Horizon_Discovery; HD+115-072
DR   Wikidata; Q54907432
RX   PubMed=19336913;
CC   Population: Caucasian.
CC   Knockout cell: Method=Homologous recombination; HGNC; 11986; TOP1 (Note=1 of 2 alleles).
CC   Sequence variation: Gene fusion; HGNC; 50800; DUX4 + HGNC; 5477; IGH; Name(s)=IGH-DUX4; Note=The translocation occurs in the silenced IGH allele (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9143; Adult B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0092 ! NALM-6
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 30-01-24; Version: 14
//
RX   PubMed=19336913; DOI=10.1248/bpb.32.724;
RA   Toyoda E., Kurosawa A., Fujii M., Adachi N.;
RT   "Heterozygous disruption of the DNA topoisomerase I gene confers
RT   cellular resistance to camptothecin in human cells.";
RL   Biol. Pharm. Bull. 32:724-727(2009).
//